Randomised placebo controlled trial on the safety and efficacy of a topical treatment for bilaternal chronic plaque psoriasis in adults

Completed

• Conditions: Mild to moderate bilaternal chronic plaque psoriasis; Skin and Connective Tissue Diseases; Psoriasis

• Registration Number: ISRCTN74459383
• Lead Sponsor: H BioJuven Pty Ltd (Australia)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2005-09-21
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 29

Inclusion Criteria

1. Participants with mild to moderate, bilateral symmetric, chronic plaque type psoriasis
2. In good general health and adequate venous access
3. Participants of childbearing age who agree to continue using birth control measures for the duration of the study
4. Males and Females between 18 and 75 years

Exclusion Criteria

1. Chronic plaque psoriasis involving more than 60% of the body surface
2. Pustular or generalized erythrodermic psoriasis
3. Use of medications which affect psoriasis during the study (e.g. systemic therapy including retinoids, methotrexate, cyclosporine, or corticosteroid and non corticosteroid topical therapy, including vitamin D analogues, tazarotene, tacrolimus)
4. Systemic therapy for psoriasis within 30 days of baseline
5. UV light therapy within 21 days of baseline
6. Topical corticosteroids within 14 days of baseline
7. Liver function tests greater than 3 times the upper limit of normal at baseline
8. Female participants who are lactating, pregnant or planning to become pregnant
9. Participants have participated in another clinical trial in the last 30 days
10. Participants unwilling to comply with study protocol
11. Any other condition, which in the opinion of the investigators could compromise the study

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
The change in erythema, scaling and induration (ESI) scores from beginning to end of treatment. Erythema (redness), scaling and induration (thickening), is scored on a 0 to 3 scale (0 = none and 3 = severe) and sum of these scores for each target lesion is the ESI score.

Secondary Outcome Measures

Name	Time	Method
1. Quality of life will be measured using the Dermatology Life Quality Index (DLQI)<br>2. Investigator and patient ratings of the efficacy of the treatment which measured on a 6 point scale: worse; unchanged; slight improvement (25%); moderate improvement (50%); marked improvement (75%); or clearance